Your browser doesn't support javascript.
loading
Anti-LAG-3 boosts CD8 T cell effector function.
Kureshi, Courtney T; Dougan, Michael; Dougan, Stephanie K.
Affiliation
  • Kureshi CT; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Program in Immunology, Harvard Medical School, Boston, MA, USA.
  • Dougan M; Program in Immunology, Harvard Medical School, Boston, MA, USA; Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Dougan SK; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Program in Immunology, Harvard Medical School, Boston, MA, USA. Electronic address: stephanie_dougan@dfci.harvard.edu.
Cell ; 187(16): 4144-4146, 2024 Aug 08.
Article in En | MEDLINE | ID: mdl-39121844
ABSTRACT
LAG-3 is the third immune checkpoint pathway successfully targeted for cancer therapy. Although ineffective as a monotherapy, combination of LAG-3 and PD-1 blockade improves survival from advanced melanoma. In this issue of Cell, two studies in mice and a human clinical trial provide insights on LAG-3 in immune regulation.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antigens, CD / CD8-Positive T-Lymphocytes / Lymphocyte Activation Gene 3 Protein Limits: Animals / Humans Language: En Journal: Cell Year: 2024 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antigens, CD / CD8-Positive T-Lymphocytes / Lymphocyte Activation Gene 3 Protein Limits: Animals / Humans Language: En Journal: Cell Year: 2024 Type: Article Affiliation country: United States